Publisher Correction: Network-based prediction of drug combinations (Nature Communications, (2019), 10, 1, (1197), 10.1038/s41467-019-09186-x);Network-based prediction of drug combinations

Nature Communications

Volumn 10, Issue 1, 2019, Pages

  Cheng, Feixiong ^a,b,c,d   Kovács, István A ^a,b   Barabási, Albert László ^a,b,e,f  

^a NORTHEASTERN UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f CENTRAL EUROPEAN UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; CAPTOPRIL; CD135 ANTIGEN; DIAZOXIDE; GUANFACINE; HYDROCHLOROTHIAZIDE; IMATINIB; IRBESARTAN; ISRADIPINE; NADROPARIN; NATALIZUMAB; NEBIVOLOL; NIFEDIPINE; OXPRENOLOL; SPIRONOLACTONE; TANDUTINIB; TELMISARTAN;

CANCER; CORRELATION; DRUG; HYPERTENSION; METHODOLOGY; NETWORK ANALYSIS; PREDICTION; PROTEIN; TOXICITY;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); COMBINATION DRUG THERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; DRUG TARGETING; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERTENSION; METHODOLOGY; MULTIPLE SCLEROSIS; NETWORK LEARNING; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN PROTEIN INTERACTION; THERAPY EFFECT; BIOLOGICAL MODEL; DRUG COMBINATION; DRUG DEVELOPMENT; DRUG EFFECT; PROCEDURES; PROTEIN ANALYSIS; TREATMENT OUTCOME;

DRUG COMBINATIONS; DRUG DEVELOPMENT; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; MODELS, BIOLOGICAL; PROTEIN INTERACTION MAPS; TREATMENT OUTCOME;

EID: 85062852393     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-019-09692-y     Document Type: Erratum

References (55)

1. Sun, X., Vilar, S. & Tatonetti, N. P. High-throughput methods for combinatorial drug discovery. Sci. Transl. Med. 5, 205rv201 (2013).
2. Jia, J. et al. Mechanisms of drug combinations: interaction and network perspectives. Nat. Rev. Drug Discov. 8, 111–128 (2009).
3. Ali, M. A., Rizvi, S. & Syed, B. A. Trends in the market for antihypertensive drugs. Nat. Rev. Drug Discov. 16, 309–310 (2017).
4. Giles, T. D. et al. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study. Lancet 383, 1889–1898 (2014).
5. Crystal, A. S. et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346, 1480–1486 (2014).
6. Tan, X. et al. Systematic identification of synergistic drug pairs targeting HIV. Nat. Biotechnol. 30, 1125–1130 (2012).
7. Zheng, W., Sun, W., & Simeonov, A. Drug repurposing screens and synergistic drug-combinations for infectious diseases. Br. J. Pharmacol. 175, 181–191 (2018).
8. Lipinski, C. & Hopkins, A. Navigating chemical space for biology and medicine. Nature 432, 855–861 (2004).
9. Bulusu, K. C. et al. Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives. Drug Discov. Today 21, 225–238 (2016).
10. Sun, Y. et al. Combining genomic and network characteristics for extended capability in predicting synergistic drugs for cancer. Nat. Commun. 6, 8481 (2015).
11. Bansal, M. et al. A community computational challenge to predict the activity of pairs of compounds. Nat. Biotechnol. 32, 1213–1222 (2014).
12. Zimmer, A., Katzir, I., Dekel, E., Mayo, A. E. & Alon, U. Prediction of multidimensional drug dose responses based on measurements of drug pairs. Proc. Natl Acad. Sci. USA 113, 10442–10447 (2016).
13. Barabasi, A. L. & Oltvai, Z. N. Network biology: understanding the cell’s functional organization. Nat. Rev. Genet. 5, 101–113 (2004).
14. Menche, J. et al. Disease networks. Uncovering disease–disease relationships through the incomplete interactome. Science 347, 1257601 (2015).
15. Guney, E., Menche, J., Vidal, M. & Barabasi, A. L. Network-based in silico drug efficacy screening. Nat. Commun. 7, 10331 (2016).
16. Cheng, F. et al. Network-based approach to prediction and population-based validation of in silico drug repurposing. Nat. Commun. 9, 2691 (2018).
17. Barabasi, A. L., Gulbahce, N. & Loscalzo, J. Network medicine: a network-based approach to human disease. Nat. Rev. Genet. 12, 56–68 (2011).
18. Vidal, M., Cusick, M. E. & Barabasi, A. L. Interactome networks and human disease. Cell 144, 986–998 (2011).
19. Yildirim, M. A., Goh, K. I., Cusick, M. E., Barabasi, A. L. & Vidal, M. Drug–target network. Nat. Biotechnol. 25, 1119–1126 (2007).
20. Hopkins, A. L. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4, 682–690 (2008).
21. Hopkins, A. L. Network pharmacology. Nat. Biotechnol. 25, 1110–1111 (2007).
22. Kalmanti, L. et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia 29, 1123–1132 (2015).
23. DeAngelo, D. J. et al. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood 108, 3674–3681 (2006).
24. Polman, C. H. et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354, 899–910 (2006).
25. Wolf, G. & Stahl, R. A. A woman with increasing weakness of the legs and irregular heartbeat who took her husband’s medication. Nephrol. Dial. Transplant. 17, 1698–1701 (2002).
26. Jia, Y. et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature 534, 129–132 (2016).
27. Brown, M. J. et al. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol. 4, 136–147 (2016).
28. Beermann, B., Groschinsky-Grind, M. & Rosen, A. Absorption, metabolism, and excretion of hydrochlorothiazide. Clin. Pharmacol. Ther. 19, 531–537 (1976).
29. Han, P., Chu, Z. X., Shen, F. M., Xie, H. H. & Su, D. F. Synergism of hydrochlorothiazide and nitrendipine on reduction of blood pressure and blood pressure variability in spontaneously hypertensive rats. Acta Pharmacol. Sin. 27, 1575–1579 (2006).
30. Maronde, R. F., Milgrom, M., Vlachakis, N. D. & Chan, L. Response of thiazide-induced hypokalemia to amiloride. JAMA 249, 237–241 (1983).
31. Greene, J. A. & Loscalzo, J. Putting the patient back together—social medicine, network medicine, and the limits of reductionism. N. Engl. J. Med. 377, 2493–2499 (2017).
32. Bibi, Z. Role of cytochrome P450 in drug interactions. Nutr. Metab. 5, 27 (2008).
33. Cami, A., Manzi, S., Arnold, A. & Reis, B. Y. Pharmacointeraction network models predict unknown drug–drug interactions. PLoS ONE 8, e61468 (2013).
34. Zhao, S. et al. Systems pharmacology of adverse event mitigation by drug combinations. Sci. Transl. Med. 5, 206ra140 (2013).
35. Tatonetti, N. P., Ye, P. P., Daneshjou, R. & Altman, R. B. Data-driven prediction of drug effects and interactions. Sci. Transl. Med. 4, 125ra131 (2012).
36. Facchetti, G., Iacono, G. & Altafini, C. Computing global structural balance in large-scale signed social networks. Proc. Natl. Acad. Sci. U.S.A. 108, 20953–20958 (2011).
37. Istvan, A. K. et al. Network-based prediction of protein interactions. Preprint at 10.1101/275529 (2018).
38. Rolland, T. et al. A proteome-scale map of the human interactome network. Cell 159, 1212–1226 (2014).
39. Rual, J. F. et al. Towards a proteome-scale map of the human protein-protein interaction network. Nature 437, 1173–1178 (2005).
40. Law, V. et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 42, D1091–D1097 (2014).
41. Zhu, F. et al. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 40, D1128–D1136 (2012).
42. Hernandez-Boussard, T. et al. The pharmacogenetics and pharmacogenomics knowledge base: accentuating the knowledge. Nucleic Acids Res. 36, D913–D918 (2008).
43. Gaulton, A. et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 40, D1100–D1107 (2012).
44. Liu, T. Q., Lin, Y. M., Wen, X., Jorissen, R. N. & Gilson, M. K. BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities. Nucleic Acids Res. 35, D198–D201 (2007).
45. Pawson, A. J. et al. The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucleic Acids Res. 42, D1098–D1106 (2014).
46. Apweiler, R. et al. UniProt: the universal protein knowledgebase. Nucleic Acids Res. 32, D115–D119 (2004).
47. Bodenreider, O. The Unified Medical Language System (UMLS): integrating biomedical terminology. Nucleic Acids Res. 32, D267–D270 (2004).
48. O’Boyle, N. M. et al. Open Babel: an open chemical toolbox. J. Cheminform. 3, 33 (2011).
49. Willett, P. Similarity-based virtual screening using 2D fingerprints. Drug Discov. Today 11, 1046–1053 (2006).
50. Smith, T. F. & Waterman, M. S. Identification of common molecular subsequences. J. Mol. Biol. 147, 195–197 (1981).
51. Cheng, F. et al. Studying tumorigenesis through network evolution and somatic mutational perturbations in the cancer interactome. Mol. Biol. Evol. 31, 2156–2169 (2014).
52. Wang, J. Z., Du, Z., Payattakool, R., Yu, P. S. & Chen, C. F. A new method to measure the semantic similarity of GO terms. Bioinformatics 23, 1274–1281 (2007).
53. Yu, G. et al. GOSemSim: an R package for measuring semantic similarity among GO terms and gene products. Bioinformatics 26, 976–978 (2010).
54. Cheng, F. et al. Prediction of polypharmacological profiles of drugs by the integration of chemical, side effect, and therapeutic space. J. Chem. Inf. Model. 53, 753–762 (2013).
55. NCBI Resource Coordinators. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 44, D7–D19 (2016).